Publications

1. Advice on a possible candidate for the conditional inclusion of teduglutide (Revestive®)

   The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to designate teduglutide (Revestive®) ...

   Report | 21-09-2023

2. Package advice for the lock procedure medicinal product zanubrutinib (Brukinsa®) for the treatment of chronic lymphocytic leukaemia (CLL)

   The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...

   Report | 31-08-2023

3. GVS advice fenfluramine (Fintepla®) for the treatment of epileptic seizures in Dravet Syndrome or Lennox-Gastaut Syndrome

   The National Health Care Institute has assessed whether fenfluramine (Fintepla®) can be included in the Medicine Reimbursement ...

   Report | 31-08-2023

4. GVS advice midazolam (Midazolam Xiromed®) for the treatment of epilepsy

   The National Health Care Institute has assessed whether oromucosal administration of midazolam (Midazolam Xiromed®) can be ...

   Report | 22-08-2023

5. GVS advice for tirzepatide (Mounjaro®) for the treatment of adults with type 2 diabetes mellitus without a very high risk of cardiovascular disease

   The National Health Care Institute has assessed whether tirzepatide (Mounjaro®) can be included in the Medicine Reimbursement ...

   Report | 14-08-2023

6. Advice - Extension of conditional inclusion procedure for ataluren (Translarna®)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to extend the conditional ...

   Report | 31-07-2023

7. GVS advice glucagon (Ogluo®) for the treatment of severe hypoglycaemia in adults and children aged 2 years and older

   The National Health Care Institute assessed whether the administration of subcutaneous glucagon (administration under the skin) ...

   Report | 28-07-2023

8. Package advice for lock procedure medicinal product darolutamide (Nubeqa®) for the treatment of metastatic prostate cancer

   The National Health Care Institute has assessed whether the medicinal product darolutamide in combination with docetaxel and ...

   Report | 28-07-2023

9. Package advice eptinezumab (Vyepti®) for the treatment of migraine

   The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...

   Report | 28-07-2023

10. Package advice for entrectinib and larotrectinib (Rozlytrek® and Vitrakvi®) for the treatment of adult and paediatric patients with solid tumours (cancer) with NTRK gene fusion

    The National Health Care Institute has assessed whether the medicinal products entrectinib and larotrectinib (Rozlytrek® and ...

    Report | 27-07-2023